Bioinformatics and in vitro study reveal the roles of microRNA-346 in high glucose-induced human retinal pigment epithelial cell damage

AIM:To study microRNAs(miRNAs)and their potential effects in high glucose-induced human retinal pigment epithelial cell damage.METHODS:We screened the GSE52233 miRNA expression dataset for differentially expressed miRNAs(DEMs).The target genes of the top 10 DEMs were predicted using miRWalk 2.0 database,followed by function enrichment and protein-protein interaction analysis.miRNA expression was determined in the human retinal pigment epithelial cell line ARPE-19 treated with high glucose(HG)by quantitative reverse transcription-polymerase chain reaction(qRT-PCR).Cell proliferation was determined using cell counting kit(CCK)-8 assay.Cell cycle,apoptosis,and reactive oxygen species(ROS)levels were determined by flow cytometry.The direct interaction between miRNA and targets was validated using dual-luciferase reporter assay.RESULTS:Thirty-nine DEMs were screened,and we predicted 125 miRNA-mRNA pairs for the top 10 DEMs,including 119 target genes of seven DEMs such as miR-346,which was upregulated in diabetic retinopathy(DR).miR-346 target genes were substantially enriched in the regulation of intracellular transport and retinoic acidinducible gene I(RIG-I)-like receptor signaling pathway.Expression of three upregulated and downregulated miRNAs were verified by qRT-PCR in HG-treated ARPE-19 cells.Expression of miR-346 was elevated in HG treated ARPE-19 cells in a dose-dependent manner.HG inhibited cell proliferation and induced apoptosis,which were partly reversed by transfecting an miR-346 inhibitor,which even decreased the ROS levels elevated due to HG.Argonaute 2(AGO2)was a target of miR-346.CONCLUSION:miR-346 is a key miRNA and plays an important role in HG-induced damage in human retinal pigment epithelial cells.

最小量巩膜扣带术治疗陈旧性视网膜脱离的疗效观察

目的:观察最小量巩膜扣带术治疗陈旧性视网膜脱离的临床效果。方法:回顾性分析2014-01/2018-09在我院行最小量巩膜扣带术的陈旧性视网膜脱离患者54例54眼的临床资料,术后随访6mo,观察视网膜复位情况和最佳矫正视力(BCVA)、眼压、眼轴、角膜散光等眼部参数情况,并根据术前视网膜脱离时间、脱离范围、是否累及黄斑和术后是否存在持续性视网膜下液(PSF)对术后BCVA改善情况进行分析。结果:本组患者初次手术后视网膜完全复位49眼(91%),其中29眼术后存在PSF。至末次随访时12眼(22.2%)BCVA提高,38眼(70.4%)BCVA无变化,4眼(7.4%)BCVA下降。术前视网膜脱离时间、脱离范围、是否累及黄斑和术后是否存在PSF对术后BCVA改善情况均有一定影响。结论:最小量巩膜扣带术治疗陈旧性视网膜脱离安全有效,但是术后视力改善与诸多因素有关。

非眼科手术后失明原因探析

非眼科手术失明(visual loss after non-ocular surgery,VLNOS)包括手术后视力丧失(postoperative visual loss)和围手术期视力丧失(perioperative visual loss),前者表现为手术中已失明或手术后的即刻失明,后者表现为围手术期的术后急性视力丧失,可见于俯卧位脊柱手术、心脏体外循环手术、头颈部手术以及面部微整形注射等治疗后,是一种少见的、极为严重的并发症。VLNOS分为可预测性和不可预测性,已引起相关学科与眼科的关注,并开始探索可能的原因并采取积极的预防措施。

无晶状体眼行IOL睫状沟缝线固定术的临床效果

目的:探讨无晶状体眼行人工晶状体(IOL)睫状沟缝线固定术的临床效果。方法:回顾性分析2015-01/2018-06行IOL睫状沟缝线固定术患者38例38眼的临床资料,包括术中和术后并发症、眼压、IOL位置,并比较手术前后视力、屈光状态。结果:术中出血6眼(16%),术后低眼压4眼(11%),高眼压11眼(29%),经治疗后恢复,IOL倾斜4眼(11%)。术后末次随访时视力较术前提高(P<0.05)。术前预留屈光度数(球镜)与术后3mo实际屈光度数(球镜)无差异(P>0.05)。结论:IOL睫状沟缝线固定术是治疗无晶状体眼安全有效的方法,但应重视相关并发症。

Magnetic nanoparticles conjugated with “RPE cell-MCP-1 antibody-VEGF antibody” compounds for the targeted therapy of age-related macular degeneration: a hypothesis

Age-related macular degeneration（AMD） is the leading cause of vision loss in the elderly throughout the world. Treatment of AMD utilizing retinal pigment epithelium（RPE） transplantation represents a promising therapy. However, simplex RPE transplantation can only replace the diseased RPE cells, but has no abilities to stop the development of AMD. It has been indicated that oxidization triggers the development of AMD by inducing the dysfunction and degeneration of RPE cells, which results in the upregulation of local monocyte chemotactic protein-1（MCP-1） expression. MCP-1 induces macrophage recruiment which triggers local inflammation. As a result, the expression of vascular endothelial growth factor（VEGF） is upregulated by MCP-1mediated inflammation and results in the formation of choroidal neovascularization（CNV）. We accordingly propose a targeted therapy of AMD by subretinal transplanting the compound of RPE cell, MCP-1 antibody, and VEGF antibody and using a magnetic system to guide RPE cell compounds conjugated with superparamagnetic iron oxide nanoparticles（SPIONs）. Furthermore, SPION-labelled RPE cells can be tracked and detected in vivo by non-invasive magnetic resonance imaging（MRI）. This novel RPE cell transplantation methodology seems very promising to provide a new therapeutic approach for the treatment of AMD.

Clinical research of EX-PRESS drainage device and modified trabeculectomy combined with intravitreal conbercept treatment for neovascular glaucoma

AIM:To evaluate the efficacy and safety of modified trabeculectomy(experimental group) and implantation of EX-PRESS drainage device(control group),combined with intravitreal conbercept injection for neovascular glaucoma(NVG).METHODS:Totally 30 patients with NVG were selected from June 2014 to June 2017,and randomly divided into experimental group and control group.All patients were underwent intravitreal conbercept(0.5 mg/0.05 mL) treatment before surgery.Modified trabeculectomy was performed in MT group,while EX-PRESS drainage device implantation was performed in EX group.The success rates,best corrected visual acuity(BCVA),intraocular pressure(IOP),filtering bleb and complications were observed and compared.RESULTS:The differences of success rate,BCVA and filtering bleb were not statistically significant 12mo after the surgery(P>0.05),however,the difference of IOP at 1d,1wk,1,3,and 6mo after surgery was statistically significant(F_(time)=390.64,P_(time)<0.0001) between two groups.The interactions between two groups in the given time showed no significant difference(F_(intergroup×time)=0.181,P_(intergroup×time)=0.57),and also there was no significant difference in IOP between the two groups(F=3.16,P=0.09).The results of pairwise comparison at each time point showed no significant difference in IOP between 1d and 1wk,3 and 6,3mo and 12mo after surgery(P>0.05),while the results at other time point indicate statistical differences(P<0.05).CONCLUSION:The modified trabeculectomy and the implantation of EX-PRESS drainage device have clinical application value in reducing IOP and postoperative complications of refractory NVG.